In Part 2 of the APEX trial, 81 AdvSM patients were treated with 150 mg of bezuclastinib, including 57 patients with SM-AHN, 11 patients with ASM and 13 patients with MCL. 68 of these patients were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback